Publicaciones en colaboración con investigadores/as de University of Sydney (91)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Combining diaries and accelerometers to explain change in physical activity during a lifestyle intervention for adults with prediabetes: A PREVIEW sub-study

    PLoS ONE, Vol. 19, Núm. 3 March

  3. Role of Eating Behavior and Stress in Maintenance of Dietary Changes During the PREVIEW Intervention

    Journal of Nutrition Education and Behavior, Vol. 56, Núm. 5, pp. 276-286

  4. Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 14, pp. 1612-1618

  5. Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease

    Gut, Vol. 73, Núm. 5, pp. 825-834

2023

  1. Associations of obesity phenotypes with weight change, cardiometabolic benefits, and type 2 diabetes incidence during a lifestyle intervention: results from the PREVIEW study

    International Journal of Obesity, Vol. 47, Núm. 9, pp. 833-840

  2. Author Correction: Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2) (npj Parkinson's Disease, (2023), 9, 1, (100), 10.1038/s41531-023-00526-9)

    npj Parkinson's Disease

  3. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347

  4. Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis

    CMAJ. Canadian Medical Association Journal, Vol. 66, Núm. 3, pp. E310-E320

  5. Differences between HbA1c and glucose-related variables in predicting weight loss and glycaemic changes in individuals with overweight and hyperglycaemia – The PREVIEW trial

    Clinical Nutrition, Vol. 42, Núm. 5, pp. 636-643

  6. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

    The Lancet. Oncology, Vol. 24, Núm. 7, pp. e293-e311

  7. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

    British Journal of Cancer, Vol. 128, Núm. 12, pp. 2283-2294

  8. Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia

    Future Oncology, Vol. 19, Núm. 5, pp. 345-353

  9. Predicting liver-related events in NAFLD: A predictive model

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 4, pp. 1240-1251

  10. Profiling the immune landscape in mucinous ovarian carcinoma

    Gynecologic Oncology, Vol. 168, pp. 23-31

  11. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

    Journal of Clinical Oncology

  12. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients

    Seminars in Hematology

  13. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients

    Seminars in Hematology

  14. SARS-CoV-2 Infection in Patients with Waldenstrom's Macroglobulinemia: A Multicenter International Cohort Study

    HemaSphere

  15. Socio-economic factors, mood, primary care utilization, and quality of life as predictors of intervention cessation and chronic stress in a type 2 diabetes prevention intervention (PREVIEW Study)

    BMC Public Health, Vol. 23, Núm. 1